CONNEQT Health completes A$5.5m placement, C2 Ventures commits A$1.5m
What's the deal? ASX-listed CONNEQT Health (ASX: CQT) has completed a A$5.5 million placement, issuing roughly 250 million new shares at A$0.022 each — a 15.4% discount to its last closing price. C2 VenturesDealroom has a profile for this one. Try Dealroom →, associated with chairman Niall Cairns and chief executive Craig Cooper, committed A$1.5 million of the total, subject to shareholder approval at an extraordinary general meeting.
The funds will go toward product inventory, new product development, marketing, enterprise growth initiatives, and working capital. CONNEQT also plans a share purchase plan on the same terms, expected to raise up to A$0.5 million.
The placement will be issued in two tranches. The first — about 161 million shares — is expected to settle on June 25, 2026. The second tranche of roughly 89 million shares awaits shareholder approval.
Why now? CONNEQT is riding a wave of commercial momentum. It reported quarterly revenue of A$2.04 million in March 2026 and exited the quarter at an annualised group revenue run-rate of roughly A$10 million.
Its flagship Pulse arterial health monitor is the primary growth engine, contributing about A$7 million in annualised revenue run-rate and averaging over 50% quarter-on-quarter growth since launch. The American Association of Retired Persons named Pulse one of the "Best Blood Pressure Monitors of 2026," giving it the highest rating for "Most Comprehensive Data."
Enterprise traction is building too, with initial pilot programmes converting to commercial contracts at a 100% rate.
What could go wrong? The placement's 15.4% discount and the issuance of 250 million new shares mean meaningful dilution for existing holders. A significant portion — the second tranche plus the chairman and chief executive's A$1.5 million commitment — still requires shareholder approval, introducing execution risk.
Heavy insider participation from C2 Ventures can signal confidence, but it also concentrates ownership further among management-linked entities. And while the revenue run-rate is growing fast, CONNEQT has not yet demonstrated sustained profitability.
The signal: CONNEQT's raise reflects a broader pattern among ASX-listed health-tech companies tapping equity markets to scale commercially validated products before reaching profitability. The strong insider backing from C2 Ventures — an investment fund linked to the company's own chairman and chief executive — and a 100% pilot conversion rate suggest genuine product-market fit in remote cardiovascular monitoring, a segment where ageing populations are driving sustained demand.
Read more: Listcorp
